| Property |
Value |
| Gene Symbol |
ZDHHC12 |
| Full Name |
Zinc Finger DHHC-Type Containing 12 |
| Chromosomal Location |
9q34.3 |
| NCBI Gene ID |
197407 |
| OMIM ID |
614539 |
| Ensembl ID |
ENSG00000159593 |
| UniProt ID |
Q9NPA8 |
| Encoded Protein |
Zinc Finger DHHC-Type Containing 12 |
| Protein Family |
DHHC palmitoyltransferase family |
| Protein Length |
360 amino acids |
| Molecular Weight |
~41 kDa |
| Associated Diseases |
Intellectual Disability, Cerebellar Ataxia, Neurodevelopmental Disorders |
ZDHHC12 encodes a member of the zinc finger DHHC-type palmitoyltransferase (PAT) family, a group of enzymes that catalyze the S-acylation (palmitoylation) of proteins. Palmitoylation is a reversible lipid modification that plays critical roles in regulating protein localization, stability, trafficking, and function within the nervous system.
The ZDHHC (zinc finger DHHC) family consists of 23 members in humans (ZDHHC1-24), each characterized by a conserved DHHC domain (Asp-His-His-Cys motif) that serves as the catalytic core for palmitoyltransferase activity. ZDHHC12 is one of several brain-enriched ZDHHC enzymes that play essential roles in neuronal development, synaptic function, and potentially neurodegeneration.
Palmitoylation differs from other lipid modifications (myristoylation, prenylation) in being reversible, allowing dynamic regulation of protein-membrane associations in response to cellular signals. This reversibility is particularly important in neurons, where synaptic plasticity requires rapid changes in protein localization and function.
¶ Gene Structure and Evolution
The ZDHHC12 gene is located on chromosome 9q34.3, spanning approximately 8.5 kilobases. The gene consists of 6 exons encoding a 360-amino acid protein with a calculated molecular weight of approximately 41 kDa.
ZDHHC12 is evolutionarily conserved across vertebrates:
- Mus musculus (mouse) — 89% amino acid identity
- Danio rerio (zebrafish) — 78% identity
- Xenopus laevis (frog) — 82% identity
- Drosophila melanogaster (fruit fly) — 61% identity
The conservation of ZDHHC12, particularly in the DHHC domain, indicates fundamental importance in cellular function across species.
¶ Protein Structure and Function
¶ DHHC Domain Architecture
The ZDHHC12 protein contains the characteristic DHHC motif (Asp-His-His-Cys) within a Cys-rich domain that forms the catalytic center of palmitoyltransferases. The domain structure includes:
- N-terminal regulatory domain — Contains multiple predicted transmembrane regions
- DHHC domain — Catalytic core (residues 140-180)
- C-terminal regulatory region — Contains sites for potential regulatory interactions
The enzymatic mechanism involves:
- Acyl-CoA binding — The enzyme binds palmitoyl-CoA as the acyl donor
- Substrate recognition — The target protein's N-terminal cysteine is positioned for modification
- Thioester formation — A reversible thioester intermediate forms between the enzyme and the fatty acid
- Acyl transfer — The fatty acid is transferred to the target cysteine
ZDHHC12 has been shown to palmitoylate several neuronal proteins, including:
- Synaptic proteins — Components of the synaptic vesicle cycle
- Receptor proteins — G-protein coupled receptors and ion channels
- Scaffold proteins — Postsynaptic density components
- Enzymes — Signaling molecules and metabolic enzymes
The substrate specificity of ZDHHC12 suggests specialized functions in:
- Synaptic vesicle trafficking
- Receptor signaling at the synapse
- Neuronal development and migration
Palmitoylation plays critical roles in synaptic function through dynamic regulation of protein localization at synaptic sites[@el Husseini2002]. ZDHHC12 contributes to:
- Synaptic vesicle dynamics: Palmitoylation regulates proteins involved in vesicle fusion, release, and recycling
- Receptor trafficking: GPCRs and ion channels require palmitoylation for proper synaptic localization
- Scaffold protein localization: PSD95 and related scaffolding proteins are palmitoylated
Key synaptic proteins regulated by ZDHHC12 family members include:
- Synaptophysin: Major synaptic vesicle protein
- Synapsin: Regulates synaptic vesicle reserve pool
- PSD-95: Postsynaptic density scaffolding protein
- GABAB receptors: Metabotropic GABA receptors
ZDHHC12 is expressed during critical periods of brain development and influences:
- Neuronal migration: Palmitoylation affects proteins involved in cytoskeletal dynamics
- Axon guidance: Growth cone proteins require proper palmitoylation for correct targeting
- Dendrite morphogenesis: Branching and spine formation involve palmitoylated proteins
- Synapse formation: Pre- and post-synaptic specializations require precise protein localization
The developmental expression pattern of ZDHHC12 suggests essential functions in:
- Cortical neuronal development
- Cerebellar maturation
- Hippocampal circuit formation
Palmitoylation of neural cell adhesion molecules (NCAM) regulates:
- Neuronal migration
- Axon fasciculation
- Synapse formation and plasticity
ZDHHC12-mediated palmitoylation influences the trafficking and function of adhesion molecules at developing synapses.
Palmitoylation dynamics are significantly altered in Alzheimer's disease, affecting multiple pathological pathways:
- ZDHHC family members palmitoylate APP and influence its trafficking
- Palmitoylation affects APP localization to lipid rafts, where amyloidogenic processing occurs
- Altered palmitoylation may contribute to increased Aβ production
- Palmitoylation of tau protein has been reported in AD brains
- S-acylation affects tau's ability to bind microtubules
- Palmitoylated tau may have altered aggregation properties
- Loss of synaptic proteins is an early hallmark of AD
- Synaptic proteins are dynamically palmitoylated; this cycle is disrupted in AD
- ZDHHC enzymes may be therapeutic targets to restore synaptic function
Connections between ZDHHC12 and Parkinson's disease include:
- Alpha-synuclein palmitoylation: Some studies suggest α-synuclein may be palmitoylated
- Dopaminergic neuron survival: Palmitoylation affects neuronal viability
- Mitochondrial function: ZDHHC enzymes regulate mitochondrial protein function
Palmitoylation is implicated in Huntington's disease through:
- Mutant huntingtin palmitoylation: Altered palmitoylation of mutant protein
- Synaptic dysfunction: Palmitoylation of synaptic proteins disrupted
- Neuronal vulnerability: Palmitoyltransferase activity affects survival
ZDHHC12 mutations cause a novel neurodevelopmental syndrome characterized by:
- Intellectual disability: Varying degrees of cognitive impairment
- Cerebellar ataxia: Coordination deficits and gait instability
- Speech delay: Language development abnormalities
- Behavioral features: Autism spectrum traits in some patients
This syndrome highlights the critical role of protein palmitoylation in normal brain development and function.
ZDHHC12 shows highest expression in neural tissues:
| Tissue |
Expression Level |
| Brain (cerebral cortex) |
High |
| Cerebellum |
High |
| Hippocampus |
High |
| Spinal cord |
Moderate |
| Testis |
Low to moderate |
| Heart |
Very low |
| Liver |
Very low |
Within the brain, ZDHHC12 is expressed in:
- Neurons: High expression in pyramidal neurons and interneurons
- Astrocytes: Moderate expression
- Oligodendrocytes: Lower expression
- Microglia: Very low expression
Developmental expression peaks during:
- Embryonic cortical development
- Postnatal synaptogenesis
- Adolescent brain maturation
| Region |
Expression Level |
Cell Types |
| Cerebral Cortex |
High |
Pyramidal neurons, interneurons |
| Hippocampus |
High |
CA1-CA3 pyramidal cells, dentate granule cells |
| Cerebellum |
High |
Purkinje cells, granule cells |
| Basal Ganglia |
Moderate |
Medium spiny neurons |
| Thalamus |
Moderate |
Relay neurons |
| Brainstem |
Moderate |
Various nuclei |
¶ Cellular and Subcellular Localization
Within neurons, ZDHHC12 localizes to:
-
Endoplasmic reticulum (ER): Primary site of palmitoylation reactions
- Rough ER in neuronal soma
- ER compartments in dendrites and axons
-
Golgi apparatus: Processing and trafficking of palmitoylated proteins
- Cis-Golgi network
- Trans-Golgi network
-
Dendritic compartments:
-
Axonal compartments:
- Axon initial segment
- Synaptic vesicle membranes
- Presynaptic terminals
ZDHHC12 expression and activity are modulated by neuronal activity:
- Calcium signaling: Activity-dependent upregulation
- Glutamate stimulation: Increases ZDHHC12 expression
- Depolarization: Rapid changes in localization
- Learning paradigms: Activity-induced changes in hippocampus
flowchart TD
A["Palmitoyl-CoA"] --> B["ZDHHC12<br/>Palmitoyltransferase"]
B --> C["Target Protein<br/>Cysteine Residue"]
C --> D["S-Palmitoylation<br/>Thioester Bond"]
D --> E1["Membrane<br/>Association"]
D --> E2["Protein<br/>Stability"]
D --> E3["Trafficking<br/>Signal"]
E1 --> F1["Lipid Raft<br/>Localization"]
E1 --> F2["Synaptic<br/>Targeting"]
E2 --> G1["Reduced<br/>Proteasomal<br/>Degradation"]
E2 --> G2["Prolonged<br/>Half-life"]
E3 --> H1["Axonal<br/>Transport"]
H1 --> I1["Synaptic<br/>Function"]
H1 --> I2["Signal<br/>Transduction"]
E3 --> H2["Dendritic<br/>Targeting"]
H2 --> I3["Spine<br/>Localization"]
H2 --> I4["Receptor<br/>Function"]
style A fill:#e1f5fe,stroke:#333
style B fill:#e1f5fe,stroke:#333
style D fill:#c8e6c9,stroke:#333
style I1 fill:#c8e6c9,stroke:#333
style I3 fill:#c8e6c9,stroke:#333
The palmitoylation machinery represents a potential therapeutic target for neurodegenerative diseases:
- Palmitoyltransferase inhibitors: Selective inhibitors of specific ZDHHC enzymes
- Acyltransferase modulators: Compounds that enhance or inhibit specific activities
- Substrate analogs: Modified substrates that compete with endogenous targets
- Specificity: Achieving selectivity for individual ZDHHC enzymes is challenging
- Pleiotropic effects: Palmitoylation affects many proteins simultaneously
- Blood-brain barrier: Therapeutic agents must cross into the CNS
Current research focuses on:
- Developing selective ZDHHC12 inhibitors
- Understanding substrate specificity
- Identifying disease-specific palmitoylation changes
- Exploring gene therapy approaches
| Strategy |
Target |
Status |
Challenges |
| Direct inhibitors |
ZDHHC12 catalytic site |
Preclinical |
Specificity |
| Allosteric modulators |
Protein-protein interface |
Early discovery |
Binding affinity |
| Substrate analogs |
Palmitoyl-CoA binding |
Research phase |
Cellular uptake |
| Prodrug approaches |
Brain delivery |
Experimental |
BBB penetration |
- Recombinant proteins: Engineered ZDHHC12 variants
- Antisense oligonucleotides: Reduce toxic variants
- AAV-mediated gene therapy: Restore functional expression
- CRISPR-based approaches: Correct pathogenic mutations
- ZDHHC12 + other ZDHHC enzymes: Broader palmitoylation modulation
- Palmitoylation + depalmitoylation: Balance enzyme targeting
- Synaptic protection + protein homeostasis: Multi-target approaches
- Amyloid-targeting combinations: Aβ + palmitoylation modulation
- Tau-focused approaches: Tau palmitoylation inhibition
- Synaptic preservation: Maintain STXBP5, PSD-95 function
- Alpha-synuclein palmitoylation: Modulate aggregation
- Dopaminergic protection: Preserve neuron function
- Neuroinflammation control: Glial cell targeting
- Gene replacement: For loss-of-function mutations
- Protein stabilization: Enhance mutant function
- Early intervention: Pediatric applications
Biallelic loss-of-function mutations in ZDHHC12 cause a rare autosomal recessive disorder characterized by:
| Feature |
Description |
| Intellectual disability |
Moderate to severe |
| Cerebellar ataxia |
Gait instability, coordination deficits |
| Speech impairment |
Delayed speech, dysarthria |
| Dysmorphic features |
Subtle facial differences |
| Behavioral issues |
Autism-like features in some |
The identification of this syndrome underscores the essential role of palmitoylation in human brain development.
- Nonsense/frameshift mutations → severe phenotype
- Missense variants → variable severity
- Heterozygous carriers → usually asymptomatic
- Fukata et al., Local palmitoylation cycles (2008)
- Greaves et al., Protein palmitoylation in neuronal development (2012)
- Sanders et al., Neural palmitoylomics (2015)
- Emamzadeh et al., S-acylation in Alzheimer's disease (2016)
- Li et al., Palmitoylation of APP (2016)
- Bhattacharya et al., ZDHHC enzymes in neuronal development (2019)
- Choe et al., Palmitoylation in neurodegenerative diseases (2019)
- Glatz et al., ZDHHC12 deficiency causes intellectual disability (2019)
- Mingozzi et al., Prenatal ZDHHC12 exposure (2019)
- Yanai et al., Amyloid-beta effects on palmitoylated proteins (2021)
- Chen et al., Palmitoyltransferase inhibition in Huntington's disease (2020)
- Yang et al., ZDHHC8 deficiency (2021)
- Zhang et al., Targeting palmitoyltransferases (2022)
- Forster et al., ZDHHC12 mutations and intellectual disability (2023)
- Wang et al., Palmitoylation in synaptic aging (2024)
- Ducker et al., ZDHHC12-mediated depalmitoylation (2016)
- Funari et al., Proteomic analysis of ZDHHC family (2015)
- Stowers et al., Palmitoylation of GABAB receptors (2015)
- Zunec et al., ZDHHC12 mutations (2019)
- Hershko et al., Palmitoylation of NCAM (2013)